| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-09 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-08 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.19 | 4e-07 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |